Frosina Guido
Mutagenesis Unit, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Brain Pathol. 2016 Nov;26(6):689-700. doi: 10.1111/bpa.12423. Epub 2016 Aug 24.
If cancer is hard to be treated, brain cancer is even more, caused by the inability of many effective drugs given systemically to cross the blood brain and blood tumor barriers and reach adequate concentrations at the tumor sites. Effective delivery of drugs to brain cancer tissues is thus a necessary, albeit not sufficient, condition to effectively target the disease. In order to analyze the current status of research on drug delivery to high grade gliomas (HGG-WHO grades III and IV), the most frequent and aggressive brain cancers, a literature search was conducted in PubMed using the terms: "drug delivery and brain tumor" over the publication year 2015. Currently explored drug delivery techniques for HGG include the convection and permeabilization-enhanced deliveries, drug-releasing depots and Ommaya reservoirs. The efficacy/safety ratio widely varies among these techniques and the success of current efforts to increase this ratio widely varies as well.
如果癌症难以治疗，那么脑癌更是如此，这是因为许多通过全身给药的有效药物无法穿过血脑屏障和血肿瘤屏障，从而无法在肿瘤部位达到足够的浓度。因此，将药物有效递送至脑癌组织是有效靶向该疾病的必要条件，尽管并非充分条件。为了分析向高级别胶质瘤（世界卫生组织III级和IV级）——最常见且侵袭性最强的脑癌——给药的研究现状，于2015年在PubMed上使用“给药与脑肿瘤”这一检索词进行了文献检索。目前针对高级别胶质瘤探索的给药技术包括对流增强给药、渗透增强给药、药物缓释库和奥马亚贮液器。这些技术的疗效/安全比差异很大，当前提高该比例的努力所取得的成功也差异很大。
